[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-herpetic-neuralgia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-herpetic-neuralgia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,95,127],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100612635","comparison-between-the-efficacy-of-ultrasound-guided-erector-spinae-plane-block-and-conventional-treatment-for-pain-management-in-patients-with-post-herpetic-neuralgia-100612635",false,"NCT07256145","Comparison Between the Efficacy of Ultrasound-guided Erector Spinae Plane Block and Conventional Treatment for Pain Management in Patients With Post-herpetic Neuralgia","Inclusion Criteria:\n\n* Patients with post-herpetic neuralgia not responding to medical treatment.\n\nExclusion Criteria:\n\n\\- 1- Patient refusal 2- Age less than 20 years or older than 70 years. 3- Systemic Infection. 4-Patients with dementia or other diseases that could have impaired their memory or cognitive function.\n\n5- Immunocompromised patients, severe osteoporosis, and uncontrolled diabetes mellitus.","ALL","20 Years","70 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","The present study aims to evaluate the efficacy of ultrasound-guided erector spinae plane block with steroids to relieve pain in cases of post-herpetic neuralgia, patient satisfaction, and record any complications post-injection.",[26],"Post-Herpetic Neuralgia","RECRUITING","2025-11-20",{"date":30,"type":31},"2025-12-01","ACTUAL",{"date":33,"type":31},"2025-08-01",{"date":35,"type":20},"2026-03-01",{"name":37,"class":38},"Alexandria University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":15,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":76,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":39},"100497203","assessing-symptom-and-mood-dynamics-in-pain-using-the-smartphone-application-soma-100497203","NCT05754190","Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA","INCLUSION CRITERIA \\[General study\\]\n\n* Chronic pain group:\n\n  * Age above 18\n  * Access to a personal smartphone and a stable internet connection\n  * Average pain intensity score of greater than 3 in the past week or\n  * Average pain interference score of greater than 3 in the past week or\n  * Average pain distress score of greater than 3 in the past week\n  * Pain duration: greater than 6 months\n* Acute pain group:\n\n  * Age above 18\n  * Access to a personal smartphone and a stable internet connection\n  * Average pain intensity score of greater than 3 in the past week\n\n    ○ or\n  * Average pain interference score of greater than 3 in the past week\n\n    ○ or\n  * Average pain distress score of greater than 3 in the past week\n  * Pain duration: less than 3 months\n  * Pain cause: Due to recent surgery, injury, acute illness, or childbirth (within the past 3 months)\n* Healthy control group:\n\n  * Age above 18\n  * Access to a personal smartphone and a stable internet connection\n  * Average pain intensity score of less than 3 in the past week\n  * Average pain interference score of less than 3 in the past week\n  * Average pain distress score of less than 3 in the past week\n  * No surgery, injury, acute illness, or childbirth (within the past 3 months)\n* In person EEG testing \\[Sub-Study only\\]:\n\n  * Same as in General App Study Above and additionally:\n  * Current diagnosis of Fibromyalgia, Chronic Low Back Pain or Failed Back Surgery Syndrome OR\n  * No current or prior history of chronic pain\n  * If participant has chronic low back pain or failed back surgery syndrome: are they planning to have either a radio-frequency ablation, back surgery, or spinal cord stimulation implant in the next few months\n  * If participant has chronic low back pain or failed back surgery syndrome: have they received insurance approval for the procedure?\n  * Ok with EEC\u002FECG measures\n\nEXCLUSION CRITERIA \\[General study\\]\n\n* Chronic pain group:\n\n  * recent injury or surgery unrelated to the pain in the past 3 months\n  * difficulty participating for technical\u002Flogistical issues (e.g., no computer, incompatible smartphone, can't commit to 4 months study participation);\n  * Not fluent in English (difficulty understanding questions)\n  * Current primary or metastatic cancer (organic cause of pain)\n* Acute pain group:\n\n  * History of Chronic Pain (Pain lasting for more than 6 months)\n  * difficulty participating for technical\u002Flogistical issues (e.g., no computer, incompatible smartphone, can't commit to 4 months study participation);\n  * Not fluent in English (difficulty understanding questions)\n  * Current primary or metastatic cancer (organic cause of pain)\n* Healthy control group:\n\nHistory of Chronic Pain (Pain lasting for more than 6 months)\n\n* difficulty participating for technical\u002Flogistical issues (e.g., no computer, incompatible smartphone, can't commit to 4 months study participation);\n* Not fluent in English (difficulty understanding questions)\n\n  -In person EEG testing \\[Sub-study only\\]: \\[will interfere with EEG data collection safety or quality\\]:\n* Same as in General App Study Above and additionally:\n* Baldness\n* Pregnancy\n* Dreadlocks\n* Left-handedness\n* Use of a wheelchair\n* Heart failure diagnosis\n* Current or prior experience with acute psychosis or mania\n* implanted pacemaker, neurostimulator or any other head or heart implants\n* require a hearing aid to hear properly\n* claustrophobia\n* metal fragments in the body",true,"18 Years",{"count":49,"type":20},800,"OBSERVATIONAL","This study relies on the use of a smartphone application (SOMA) that the investigators developed for tracking daily mood, pain, and activity status in acute pain, chronic pain, and healthy controls over four months.The primary goal of the study is to use fluctuations in daily self-reported symptoms to identify computational predictors of acute-chronic pain transition, pain recovery, and\u002For chronic pain maintenance or flareups. The general study will include anyone with current acute or chronic pain, while a smaller sub-study will use a subset of patients from the chronic pain group who have been diagnosed with chronic low back pain, failed back surgery syndrome, or fibromyalgia. These sub-study participants will first take part in one in-person EEG testing session while completing simple interoception and reinforcement learning tasks and then begin daily use of the SOMA app. Electrophysiologic and behavioral data from the EEG testing session will be used to determine predictors of treatment response in the sub-study.",[53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75],"Chronic Pain","Acute Pain","Post Operative Pain","Fibromyalgia, Primary","Fibromyalgia, Secondary","Fibromyalgia","Irritable Bowel Syndrome","Chronic Headache Disorder","Chronic Migraine","Chronic Pelvic Pain Syndrome","Temporomandibular Joint Disorders","Endometriosis-related Pain","Arthritis","Chronic Low-back Pain","Failed Back Surgery Syndrome","Post Herpetic Neuralgia","Neuropathic Pain","Painful Diabetic Neuropathy","Painful Bladder Syndrome","Trauma-related Wound","Trauma, Multiple","Chronic Pain Syndrome","Chronic Shoulder Pain",[77,78,79,80,81,82,83,84,85],"digital health","e-health","smartphone application","chronic pain","acute pain","symptom tracking","experience sampling methodology","ecological momentary assessment","pain self-management","2025-09-16",{"date":88,"type":31},"2025-09-19",{"date":90,"type":31},"2023-06-20",{"date":92,"type":20},"2026-05-30",{"name":94,"class":38},"Brown University",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":15,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":21,"phases":106,"briefSummary":107,"conditions":108,"keywords":117,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":39},"100373633","closed-loop-deep-brain-stimulation-for-refractory-chronic-pain-100373633","NCT04144972","Closed-Loop Deep Brain Stimulation for Refractory Chronic Pain","Closed-Loop Deep Brain Stimulation for Refractory Chronic Pain Using Summit RC+S","Inclusion Criteria:\n\n1. Age 22-80 years old\n2. Clinical diagnosis of a refractory chronic pain syndrome including\n\n   1. post-traumatic pain syndromes (e.g. root avulsions, nerve crush injuries, spinal cord injury)\n   2. postsurgical pain syndromes (e.g., postmastectomy syndrome, post-thoracotomy syndrome, phantom limb pain, post-surgical spinal pain)\n   3. postherpetic neuralgia\n   4. complex regional pain syndrome\n   5. atypical facial pain\n   6. central pain syndromes (e.g. post-stroke pain, multiple sclerosis pain, post-radiation pain)\n   7. post-radiation plexopathy\n3. Two or more years or more of medically refractory severe pain\n4. Average daily pain for the past 30 days reported as \\>6 on a 0-10 numeric rating scale (NRS)\n5. Pain that fluctuates over a range of at least 3 points on the NRS\n6. Patient has failed at least two pain medications from different classes as determined by a neurologist or pain management specialist with stable doses of medications for 30 days prior to baseline visit.\n7. Lack of a surgically correctible etiology for the pain as determined by 2 independent surgeons\n8. Ability to speak \u002F read English\n9. Capable of understanding and providing informed consent\n10. Absence of significant cognitive impairment - score of 25 or greater on the Montreal Cognitive Assessment (MoCA)\n11. Successful detection of pain biomarkers or positive symptomatic response to inpatient stimulation trial period if performed.\n\nExclusion Criteria:\n\n1. Major medical co-morbidities increasing the risk of surgery including uncontrolled hypertension, coagulopathy, severe diabetes, major organ system failure, active infection or history of implant related infections, immunocompromised state or malignancy with \\\u003C 5 years life expectancy\n2. Presence of cardiac pacemakers\u002Fdefibrillators, implanted medication pumps, intra-cardiac lines, any intracranial implants (e.g., aneurysm clip, shunt, cochlear implant, electrodes) or other implanted stimulators not compatible with RC+S system\n3. Pregnancy or breast feeding: all women of child bearing potential will have a negative urine pregnancy test prior to undergoing their surgical procedure.\n4. Active depression (BDI \\> 20), Suicide attempt \\\u003C\u002F= 12 months or imminent suicide risk, or other untreated or uncontrolled psychiatric illness that evaluating psychiatrist would recommend exclusion of patient after neuropsychiatric evaluation.\n5. History of substance abuse in past 3 years\n6. Inability to stop anticoagulation or platelet anti-aggregation therapy for surgery and recovery.\n7. Implantable hardware not compatible with MRI or with the study.\n8. MR abnormalities that suggest an alternative diagnosis or contraindicate surgery\n9. Previous cranial ablative surgery.\n10. Previous deep brain stimulation surgery using an RC+S incompatible system\n11. Major neurological disorder other than the one that led to the chronic pain including epilepsy or a neurodegenerative condition including inability to recharge the device.\n12. Requires diathermy, electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS)\n13. Allergies or known hypersensitivity to materials in the Summit RC+S system\n14. Patients may be excluded from enrollment due to a condition that, in the judgment of the PI, significantly increases risk or reduces significantly the likelihood of benefit from DBS.","22 Years","80 Years",{"count":105,"type":20},12,[23],"Chronic pain affects 1 in 4 US adults, and many cases are resistant to almost any treatment. Deep brain stimulation (DBS) holds promise as a new option for patients suffering from treatment-resistant chronic pain, but traditional approaches target only brain regions involved in one aspect of the pain experience and provide continuous 24\u002F7 brain stimulation which may lose effect over time. By developing new technology that targets multiple, complimentary brain regions in an adaptive fashion, the investigators will test a new therapy for chronic pain that has potential for better, more enduring analgesia.",[109,110,111,68,112,113,114,115,116],"Spinal Cord Injuries","Nerve Injury","Pain, Postoperative","Complex Regional Pain Syndromes","Post-Stroke Pain","Post Radiation Brain Injury","Post Radiation Plexopathy","Nerve Root Avulsion",[53],"2025-07-02",{"date":120,"type":31},"2025-07-08",{"date":122,"type":31},"2019-10-24",{"date":124,"type":20},"2030-10-24",{"name":126,"class":38},"University of California, San Francisco",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":46,"sex":15,"minAge":47,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":21,"phases":137,"briefSummary":139,"conditions":140,"keywords":145,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":39},"100532897","phase-1-a-mad-study-to-evaluate-the-safety-tolerability-and-pkpd-of-in1011-n17-in-healthy-volunteers-and-phn-patients-100532897","NCT06218784","A MAD Study to Evaluate the Safety, Tolerability and PK\u002FPD of iN1011-N17 in Healthy Volunteers and PHN Patients.","A Randomized, Double-blind, Placebo-controlled, Multiple-Ascending Dose Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetic\u002FPharmacodynamic Properties of iN1011-N17 After Oral Administration in Healthy Volunteers and Post-Herpetic Neuralgia Patients and to Assess the Relative Bioavailability of Mesylate vs Hydrochloride Salt Capsules in Healthy Volunteers","Inclusion Criteria:\n\nHealthy Volunteers\n\n1. Healthy male and female adults, aged 18 to 55 years of age (inclusive) at the time of consent.\n2. Body mass index (BMI = body weight (kg)\u002F\\[height (m)\\]2) between 18 kg\u002Fm2 and 32 kg\u002Fm2 (inclusive) at the time of Screening, and a minimum weight of 45 kg (inclusive).\n3. Clinically acceptable pulse rate, RR, and tympanic body temperature (pulse rate between 45 and 100 beats per minute \\[bpm\\]; SBP between 90 and 140 mmHg; DBP between 50 and 90 mmHg; RR between 12 and 22 breaths\u002Fmin; tympanic body temperature between 35.5°C and 37.7°C at Screening and Day -1). Measurements are to be recorded after a minimum of 5 minutes of resting in sitting or supine position\n\n   For Healthy Volunteers and Post-Herpetic Neuralgia Patients\n4. Clinical laboratory values within normal range as specified by the testing laboratory at Screening and Day -1, unless deemed not clinically significant by the Investigator.\n5. All participants (excluding those who are exclusively in same-sex relationships, who are postmenopausal or have an exclusive partner who is postmenopausal) must agree to use a highly effective method of contraception throughout the study and for at least 30 days for females or 90 days for males after the last dose of IP. Female participants must not be breastfeeding, lactating, or pregnant during the study period.\n\n   Female participants are required to be on their chosen contraceptive for at least 7 days before dosing.\n\n   Female participants, where their sole, male sexual partner is vasectomized, must provide a verbal confirmation of azoospermia (90 days following the procedure) which should be recorded in the source documents by the Investigator.\n\n   The minimum timeframe for pre-dose vasectomy for male participants is ≥ 12 weeks, unless they are the sole sexual partner of a female participant as outlined above.\n\n   Male participants who are sexually active must use a condom combined with use of a highly-effective method of contraception for the female partner (excluding those who have had a vasectomy or whose partner is postmenopausal). Confirmation of the female partner's contraceptive information must be provided verbally by the male participant and should be recorded in the source documents by the Investigator. The postmenopausal status of the female partner must be confirmed verbally by the male participant and should be recorded in the source documents by the Investigator.\n6. Cognitively capable of understanding the provided information and able to fully comply with protocol requirements.\n7. Written informed consent prior to the commencement of any study procedures.\n8. Willing and able to perform the necessary visits to the investigational site\u002Finstitution.\n9. In good general health at the Investigator's discretion, with no significant medical history, and with no clinically significant abnormalities on physical examination at Screening and before the first dose of IP.\n\n   Post-Herpetic Neuralgia Patients\n10. Male and female adults aged 50 to 75 years of age (inclusive) at the time of consent.\n11. Clinically acceptable blood pressure (BP), pulse rate, RR, and tympanic body temperature (SBP between 90 and 140 mmHg; DBP between 50 and 95 mmHg; pulse rate between 45 and 100 bpm; RR between 12 and 22 breaths\u002Fmin; tympanic body temperature between 35.5°C and 37.7°C) at Screening and Day -1. Measurements are to be recorded after a minimum of 5 minutes of resting in sitting or supine position.\n12. BMI (body weight (kg)\u002F\\[height (m)\\]2) between 18 kg\u002Fm2 and 40 kg\u002Fm2 (inclusive) at the time of Screening, and a minimum weight of 45 kg (inclusive).\n13. A diagnosis of neuropathic pain of PHN is confirmed when the pain for \\>3 months after the herpes zoster rash is healed, with the pain area of a continuous area of affected rash.\n14. Douleur Neuropathique 4 (DN4) score ≥4 at Screening.\n\nExclusion Criteria:\n\nFor Healthy Volunteers and Post-Herpetic Neuralgia Patients\n\n1. Presence or history of carcinoma, hepatic, renal, neurological, pulmonary (except for childhood asthma), endocrine, hematologic, cardiovascular, or genitourinary disease that, in the opinion of the Investigator, may affect the evaluation of the IP or place the participant at undue risk (except for conditions that are stable on medications).\n2. Presence of any underlying physical or psychiatric condition (except for conditions that are stable on medications) that, in the opinion of the Investigator, would undermine participant compliance to protocol requirements.\n3. Presence or history of gastrointestinal disease (e.g., peptic ulcer, gastritis, gastric cramp, gastroesophageal reflex disease, Crohn's disease) or history of gastrointestinal surgery (except simple appendectomy or herniorrhaphy) that may affect assessment of safety and PK characteristics of the IP.\n4. Presence or history of central nervous system disease that may affect assessment of safety and PK characteristics of the IP.\n5. Presence of herniated disc (inter-vertebral, cervical or both) or history of related disease that, in the opinion of the Investigator, may affect assessment of safety and PK characteristics of the IP.\n6. History of hypersensitivity to iN1011-N17 or to any of its components.\n7. History of allergy or sensitivity to sulfonamides, hay fever, asthma, eczema, food allergies and\u002For allergies to other medications. Participants with asymptomatic, untreated, seasonal allergies at the time of dosing may be considered for inclusion on a case-by-case basis- PI and Sponsor approval must be obtained prior to randomization.\n8. Any abnormal 12-lead ECG findings at Screening and Day -1, deemed by the Investigator or designee to be clinically significant.\n9. Positive test for hepatitis B surface antigen (HBsAg), hepatitis C (HCV), or human immunodeficiency virus (HIV) at Screening.\n10. Positive urine drug screen test (including methamphetamines, opiates, cocaine, cannabinoids, phencyclidine, benzodiazepines, barbiturates, methadone, tricyclic antidepressants, and amphetamines) or alcohol breath test at Screening and Day -1. Repeated tests will be allowed at the discretion of the Investigator for suspected false positives.\n11. Any of the following laboratory abnormalities within 14 days of the first treatment day:\n\n    * Platelet count \\\u003C 100,000 cells\u002Fmm3\n    * Total neutrophil count \\\u003C 1500 cells\u002Fmm3\n    * Serum creatinine ≥ 1.5 x upper limit of normal (ULN)\n    * Alanine aminotransferase (ALT) \\> 3.0 x ULN\n    * Aspartate aminotransferase (AST) \\> 3.0 x ULN\n    * Alkaline phosphatase \\> 2.0 x ULN\n    * Bilirubin \\> 1.5 x ULN\n    * Temperature ≥ 38°C or any other evidence of an infection\n12. Use of any prescription drugs (except the ones mentioned in Section 7.4.1) within 14 days, and over the counter (OTC) medications, herbal remedies (including St John's Wort), dietary supplements or vitamins within 7 days, or five half-lives of the product, whichever is longer, before the first dose of IP and for the duration of the study without prior approval of the Investigator and the MM. This includes analgesics such as paracetamol and non-steroidal anti-inflammatories (for healthy volunteers only).\n13. The use of any IP or investigational medical device within 30 days prior to Screening, or five half-lives of the product, whichever is longer.\n14. Blood or plasma donation of more than 450 mL within 90 days before the first dose of IP and for the duration of the study. It is recommended that blood\u002Fplasma donations not be made for at least 30 days after study completion.\n15. History of alcoholism, substance or drug abuse-related disorders deemed significant by the Investigator (or designee) (i.e., participants consuming \\> 21 units of alcohol per week for males and \\> 14 units of alcohol per week for females in the 90 days prior to dosing will be excluded. One unit of alcohol equals ½ pint \\[285 mL\\] of beer or lager, 1 glass \\[125 mL\\] of wine, or 1\u002F6 gill \\[25 mL\\] of spirits).\n16. Use of more than 5 nicotine-based products (including smoking tobacco, smokeless tobacco, and nicotine patches) per week, within 90 days prior to Screening. Volunteers must have a negative urine cotinine test at both Screening and Day -1 and refrain from the use of any nicotine-based products for the duration of the study.\n17. Consumption of beverages or foods that contain grapefruit, star fruit, pomelos, or products containing these fruits, from 7 days, or from the time that is deemed significant by the Investigator, and products containing caffeine (e.g., coffee, green tea, black tea, and sodas) from 48 hours before the first dose of IP until discharge from the study unit (includes the period between Periods 1 and 2 in Part 2).\n18. Unwilling to refrain from strenuous exercise from 48 hours prior to admission to the investigational site\u002Finstitution and for the duration of the study, where strenuous exercise is defined as that which requires significant effort, energy, or strength, such as lifting weights or running.\n19. Any other reason that, in the opinion of the Investigator, may affect assessment of safety, PK, or PD characteristics of the IP.\n20. Have previously completed or withdrawn from this study or any other study investigating iN1011-N17 or have previously received the IP (for healthy volunteers only).\n21. Received an investigational vaccine within 6 months, a live attenuated vaccine within 60 days, or a registered vaccine within 14 days prior to the Day -1 (Baseline visit).\n\n    Post-Herpetic Neuralgia Patients\n22. PI-NRS score of PHN-associated neuropathic pain over the last 24 hours at randomization of ≥9 or at least a daily pain score of ≥9 during the Washout Period.\n23. Previous use of neurolytic block (e.g. chemical neurolytic block using phenol or ethyl alcohol, or radiofrequency thermocoagulation) or neurosurgical therapy for current PHN.\n24. Other severe pain or the presence of other skin diseases or pain at the site of the rash at Screening or randomization unrelated to PHN, that may confound the assessment of PHN.\n25. Participants who are unable or unwilling to cease the use of all pain medications, prescription and otherwise, as of the first day of the study Washout Period and until after Day 14 of the study. This includes all lamotrigine, carbamazepine, oxcarbazepine, mexiletine, valproate, lidocaine, lacosamide, amitriptyline, topiramate, selegiline, rasagiline medications. This excludes the use of paracetamol provided that a participant is able and willing to utilize a maximum of 4 g of paracetamol per 24-hour period as of the first day of the study Washout Period and until after Day 14 of the study. Common and approved medications for PHN patients are permitted if part of a stable treatment regimen (please refer to Section 7.4.1 for a list of permitted medications).\n26. Participants who are unable or unwilling to cease the use of prohibited medication (in Section 7.4.1) during the whole study period. Have previously received the IP or any other investigational drug\u002Fdevice within 30 days or 5 half-lives, whichever is greater.","75 Years",{"count":136,"type":20},64,[138],"PHASE1","This study is a 3-part, Double-blind, Randomized, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics\u002FPharmacodynamic properties of iN1011-N17 after Oral Administration in Healthy Volunteers and Post-Herpetic Neuralgia patients, and to assess the relative bioavailability of Mesylate vs Hydrochloride salt capsules of iN1011-N17 in Healthy volunteers.",[68,141,142,69,53,143,144],"Pain","Osteoarthritis","Dorsal Root Ganglion","Nav 1.7",[144,146,147,148,141,149,150,151,152,153,154,155],"Nav 1.7 inhibitor","Postoperative pain","Chemotherapy-induced neuropathic pain","Neurological Pain","Sodium Channel","Action Potential","Voltage Gated Sodium Channel","DRG Voltage Gated Sodium Channel 1.7","Sodium Channel 1.7","Volatage Gated Sodium Channel 1.7","2024-06-20",{"date":158,"type":31},"2024-06-24",{"date":160,"type":31},"2022-11-11",{"date":162,"type":20},"2024-07-29",{"name":164,"class":165},"iN Therapeutics Co., Ltd.","INDUSTRY"]